[go: up one dir, main page]

WO2003103513A1 - Dispositif d'anastomose, methode d'ouverture et anastomose chirurgicale par voie endoscopique - Google Patents

Dispositif d'anastomose, methode d'ouverture et anastomose chirurgicale par voie endoscopique Download PDF

Info

Publication number
WO2003103513A1
WO2003103513A1 PCT/SE2003/000980 SE0300980W WO03103513A1 WO 2003103513 A1 WO2003103513 A1 WO 2003103513A1 SE 0300980 W SE0300980 W SE 0300980W WO 03103513 A1 WO03103513 A1 WO 03103513A1
Authority
WO
WIPO (PCT)
Prior art keywords
anastomotic device
nucleic acid
vessel
anastomotic
pat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2003/000980
Other languages
English (en)
Inventor
Olli KERÄNEN
Olli-Pekka LEPPÄNEN
Kristina Eneling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finnish Immunotechnology Ltd
Original Assignee
Finnish Immunotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Finnish Immunotechnology Ltd filed Critical Finnish Immunotechnology Ltd
Priority to AU2003239015A priority Critical patent/AU2003239015A1/en
Publication of WO2003103513A1 publication Critical patent/WO2003103513A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/064—Blood vessels with special features to facilitate anastomotic coupling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/11—Surgical instruments, devices or methods for performing anastomosis; Buttons for anastomosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/11—Surgical instruments, devices or methods for performing anastomosis; Buttons for anastomosis
    • A61B2017/1103—Approximator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/11—Surgical instruments, devices or methods for performing anastomosis; Buttons for anastomosis
    • A61B2017/1107—Surgical instruments, devices or methods for performing anastomosis; Buttons for anastomosis for blood vessels

Definitions

  • the present invention relates to an anastomotic device and a method for open and endoscopic surgical anastomosis of blood vessels, such as arteries and veins, ducts, lumens or other tubular organs in endoscopic and/or open surgery, in particular for reinforcement of a vessel, and in particular with regard to arterial connections.
  • blood vessels such as arteries and veins, ducts, lumens or other tubular organs in endoscopic and/or open surgery, in particular for reinforcement of a vessel, and in particular with regard to arterial connections.
  • vascular and by-pass surgery is a common modality for the treatment of occlusive vascular disease.
  • Surgery typically involves a surgical incision and an exposure of the occluded vessel, whereupon a graft is attached to a sidewall of a target vessel or conduit.
  • Mammary arteries, radial arteries, saphenous veins, or synthetic grafts are commonly used to join the occluded vessel (hereinafter the conduit distally of the occlusion).
  • the proximal end of the by-pass graft is secured to the suitable conduit upstream the occlusion, e.g.
  • occluded or diseased vessel tissue such as a carotid artery or femoral artery can be similarly treated. Also in the same type of surgery any conduit can be arranged between an artery and a vein in dialysis patients.
  • Vascular anastomosis involves the attachment of vascular grafts to vessels in a patient.
  • Anastomosis is an end-to-side anastomosis, which generally involves attaching an end of a graft to a sidewall of a target vessel at an opening in the sidewall.
  • Another type is an end-to-end anastomosis, which generally involves attaching the end of a graft to the end of a target vessel.
  • sutures or staples accomplish the attachment.
  • any protuberances, diameter changes, into the lumen could obstruct blood flow and may produce turbulence and increasing the risk of clotting and restenosis.
  • the difference in size between the larger internal diameter of the bypass graft conduit and the typically smaller native artery may also produce unwanted turbulence in the blood. All of these characteristics can greatly diminish the effectiveness of the graft.
  • tubular graft may be either natural body tissue extracted from elsewhere in the patient's body, an artificial graft structure, or a combination of natural and artificial structures.
  • a graft connector that can be installed during more traditional surgical procedures.
  • a graft connector It is important for a graft connector to be easy and quick to install (whether percutaneously or surgically), but to be secure after installation. It is typically preferable for a graft connector to be relatively flexible after installation so that it does not form an unnaturally rigid structure in the patient's body.
  • Atherosclerosis is a progressive disease process in which the flow within the lumen of an artery becomes restricted by a blockage, typically referred to as an atherosclerotic plaque.
  • a blockage of an artery can result in pain, dysfunction and even death.
  • Numerous methods have been employed over the years to revascularize the tissue downstream of an arterial blockage. These methods include bypass grafting— using artificial, in-situ venous, or transplanted venous grafts, as well as angioplasty, atherectomy and most recently, laser transmyocardial revascularization. Bypass grafting has been extremely successful; however, the procedure requires extensive surgery.
  • transthoracic endoscopic procedures such as the transthoracic endoscopic procedure being pursued by the company, Heartport, Inc. and Cardiothoracic Systems, Inc.
  • transmyocardial laser revascularization a technique in which small holes are drilled through the wall of the heart looks promising, the method of action is not yet well understood, and problems exist with the use of laser energy to create the channels.
  • clinicians are still very interested in the technique because is has the potential to be minimally invasive, and does not require the patient to be placed on cardiopulmonary bypass.
  • the cardiac veins may either be arterialized, or may be simply used as by-pass grafts. There is no literature to suggest that this has been ever been attempted. While in-situ by-pass grafts have been made in the periphery, still an incision is made to attach and ligate the vein ends.
  • Another procedure, which bears some resemblance to this technique, is called the TIPS procedure— transjugular intrahepatic portosystemic shunt. In this procedure a stent is advanced into liver tissue to connect the portal vein to the inferior vena cava.
  • T-shaped graft conduits of hitherto used design One major problem of the T-shaped graft conduits of hitherto used design is the confluence of body liquid partly from the occluded area side, and partly from the graft conduit side. These fluid streams together forms a flow, which is larger than the single stream, which means that there is a risk for further occlusions or other complications.
  • the native blood vessel, duct, lumen or tubular organ has a wall with an opening provided therein.
  • the system comprises an anastomosis device for connecting the graft conduit to the native blood vessel, duct, lumen or tubular organ to establish a passageway for carrying fluid, e.g., blood, between the graft conduit and the native vessel.
  • an anastomotic device comprising a tubular graft connector comprising a tube, wherein the tube is expandable, it is provided with a locking device locking the tube in an unexpanded position, as well as a releasing means arranged to release the locking device after an insertion into a vessel, duct, lumen etc.
  • the deployment instrument is arranged to dilate a portion of the native vessel contiguous with the opening to facilitate the introduction of at least a portion of the anastomosis device within the native vessel.
  • the anastomosis device includes a passageway extending therethrough, which decreases in cross-sectional area to provide a path for fluid, e.g., blood, to flow therethrough between the graft conduit and the native vessel while minimizing turbulence therein.
  • the device is intended to facilitate function of the anastomosis (by e.g. providing an unobstructed flow). This can be obtaiden by a mere design of the device or by introducing pharmacologically active agents as such or through gene transfer to the tissues surrounding the device.
  • the device is intended to improve body ' s response to the device by promoting healing and inhibiting pathological tissue growth.
  • the device is intended to improve body ' s defences against micro organisms which may cause infection and/or the function of the anastomosis.
  • Anastomotic device comprising a tubular graft connector comprising a tube, wherein the tube is expandable, it is provided with a locking device locking the tube in an unexpanded position, as well as a releasing means arranged to release the locking device after an insertion into a vessel, duct, lumen etc.
  • the anastomotic device comprises an the expandable tube consists of a net mesh structure (11), where the meshes have a polygonal form having at least four corners, and which in non-expanded position are stretched.
  • the anastomotic device comprisesthe polygonal form is quadratic, creating a rhomboidal form when expanded.
  • the anastomotic device comprisesthe polygonal form is hexagonal.
  • the anastomotic device comprises the device is further wholly or partly covered by a tightening cover.
  • the expansion locking device consists of a thread wound to and fro on either side of the anastomotic device outgoing from at least one releasing thread extending along the anastomotic device.
  • the expansion locking device consists of a helix thread forming the expandable parts of the anastomotic device and locked in an extended position and arranged to be released/unlocked to allow the expandable part to expand by the helix reverting to an original diameter.
  • the cover is provided with a pharmaceutical wound healing supporting entity.
  • the cover with a pharmaceutical wound healing supporting entity is a low-molecular weight compound.
  • the compound is a superoxide dismutase mimic.
  • the cover with a pharmaceutical wound healing supporting entity is a nucleic acid present in a biologically compatible formulation, characterized in that said nucleic acid encodes a translation or transcription product capable of promoting wound healing.
  • the nucleic acid is GTU® (Gene Transport Unit).
  • the nucleic acid is present in the biologically compatible formulation in naked form.
  • the nucleic acid is present in a liposome.
  • the nucleic acid is has been introduced in a viral vector selected from the group consisting of retrovirus, Sendai virus, adeno associated virus, adenovirus, lentivirus, baculovirus.
  • the nucleic acid is an artificial chromosome.
  • the nucleic acid is oligonucleotide. In a preferred embodiment the anastomotic device the nucleic acid is aptamer.
  • the nucleic acid encodes a superoxide scavenger molecule.
  • the nucleic acid encodes extracellular superoxide dismutase.
  • the nucleic acid encodes endothelial mitogen.
  • the endothelial mitogen belongs to the platelet-derived growth factor (PDGF) superfamily.
  • PDGF platelet-derived growth factor
  • the anastomotic device the endothelial mitogen belongs to the vascular endothelial growth factor (VEGF) family.
  • VEGF vascular endothelial growth factor
  • Another aspect of the invention encompasses a method for mending a vessel or to provide a by-pass of an occlusion of a vessel or the similar in a body, whereby an anastomotic device according to the above given definitions, is provided at either end of a vessel to be mended, or is inserted into a vessel to be by-passed and is connected to an occlusion circumventing vessel, allowing the anastomotic device to expand by eliminating the releasing means thereby providing a tight seal of the vessel(-s) in question.
  • FIG. 1 shows a side view of one preferred embodiment of the present invention
  • FIG. 2 shows a side view of a further preferred embodiment of the present invention
  • FIG. 3 shows a side view of another preferred embodiment of the present invention.
  • FIG. 4 shows the device according to FIG. 1 in an extended form
  • FIG. 5 shows a detail of the locking device used
  • FIG. 6 shows a device of the invention as inserted into a vessel
  • FIG. 7 shows a device of the invention as used in by-pass surgery.
  • the drawing shows a substantially tubular medical graft conduit 1 comprising a net structure 11 to be brought into a vessel, V, and providing a tubular body for reinforcing a vessel.
  • the net structure 11 consisting of hexagonal cells 12, is, in a non-inserted position, extended or elongated, whereby the cells have adopted an extended form, as evident from Fig. 3.
  • the net structure or conduit 1 is covered by a layer 2 of biocompatible expandable material. The cover may only cover a part of the tubular structure as evident from FIGs. 1-4.
  • the polygonal cells may be quadratic forming a rhomboidal structure when expanded, being hexagonal, which is preferred, or being octagonal, decagonal or even dodecagonal. However, they should have an even number of corners to provide for a good expanded shape.
  • the cover 2 may be provided with any suitable pharmaceutical composition to inhibit rejection, to inhibit bacterial growth, or to support tissue growth such as any growth factor known in the art, synthesized or extracted from a natural source. Any other wound healing supporting pharmaceutical composition or drug entity can be used as well.
  • the cover is preferably made of an porous material providing apertures of 60 to 200 um, arranged about 60 urn from each other. This facilitates in-growth of new vessel tissue into the graft.
  • the material of the graft can be any native graft material used, or any synthetic material used and known to the one skilled in the art.
  • a synthetic material is used when the graft is made expandable using a net structure or a helix for primarily reducing the diameter.
  • the net structure is made of any biocompatible material which is not rejected by the body, and which allows the walls of the vessel or duct to grow over it to provide a new biological lumen.
  • biocompatible material are biocompatible polymers known in the art or a metal such as titanium, which has proved to be an efficient material in prosthetic surgery.
  • biomaterials are those that provide sufficient rigidity for their intended purposes in vivo.
  • the biomaterial will be of sufficient rigidity to allow the graft to retain graft potency in the course of its intended use.
  • the choice of implant material will differ according to the particular circumstances and the site where the vascular or tissue implant is implanted.
  • Vascular prostheses are made of biomaterials, selected from the group consisting of e.g. tetrafluoroethylene polymers, aromatic/aliphatic polyester resins, polyurethanes, and silicone rubbers. However, any type of biocompatible microporous mesh may be used.
  • the said biomaterials can be combined with each other or other substances, such as polyglycolic acid, polylactic acid, polydioxone and polyglyconate.
  • Preferred are expanded polytetrafluoroethylene and Dacron.
  • Dacron may be with or without velour, or modified in some other way. Dacron is usually woven, braided or knitted and suitable yarns are between 10 and 400 deniers.
  • the nodal regions of ePTFE are composed of nonporous PTFE that serves to provide tear resistance (e.g. for sutures and resistance to aneurismal dilatation).
  • the intemodal regions are composed of fibres of PTFE, which serve to connect the nodes with the spaces between the fibres providing the porosity referred to herein.
  • the nodal size can be expressed as the percentage of the tissue-contacting surface that is composed of nodal PTFE.
  • the distance between nodes can be expressed as the average fibril length.
  • the porosity is commonly expressed as the intemodal distance (i.e. the average distance from the middle of one node to the middle of the adjacent node).
  • Preferred ePTFE materials have nodes of sufficient size and frequency to provide adequate strength (e.g., with respect to aneurismal dilatation) and intemodal regions of sufficient frequency and fibre length to provide adequate porosity (to allow for capillary endothelialisation). Given the present specification, those skilled in the art will be able to identify and fabricate devices using biomaterials having a suitable combination of porosity and rigidity.
  • Biomaterials are preferably porous to allow the attachment and migration of cells, which may be followed by the formation and growth of capillaries into the surface.
  • Suitable pores can exist in the form of small channels or passages, which start at an external surface and extend partially or completely through the biomaterial.
  • the cross sectional dimensions of the pore capillary diameter are greater than 5 microns and typically less than 1 mm.
  • the upper pore size value is not critical as long as the biomaterial retains sufficient rigidity; however it is unlikely that useful devices would have a pore size greater than about 1mm.
  • Such pore dimensions can be quantified in microscope.
  • several modifications of the graft materials and surfaces can be made, such as precoating with, for example, proteins (see e.g.
  • the implant can be constructed as a hybrid of different intemodal distances for the inner and outer surfaces, such as 60 microns as an outer value and 20 microns as an inner value, for the intemodal distances (HYBRID PTFE). Also, more layers with different intemodal distances may be used.
  • biodegradable vascular implants may be used in connection with the compositions, devices and methods of this invention.
  • biodegradable and chemically defined polylactic acid, polyglycolic acid, matrices of purified proteins, semi-purified extra cellular matrix compositions and also collagen can be employed.
  • naturally occurring autogenic, allogenic and xenogenic material such as an umbilical vein, saphenous vein, native bovine artery or intestinal sub-mucosal tissue may be used as a vascular implant material. Examples of clinically used grafts are disclosed in 4,187,390, 5,474,824 and 5,827,327.
  • Biodegradable or bioabsorbable materials such as homopolymers e.g. poly- paradioxanone, polylysine or polyglycolic acid and copolymers; e.g., polylactic acid and polyglycolic acids or other bio materials, may be used either alone or in combination with other materials as the vascular graft material, as long as they provide the required rigidity.
  • other biological materials such as intestinal submucosa, matrices of purified proteins and semi-purified extra cellular matrix compositions may be used.
  • vascular grafts will both deliver the gene composition and also provide a surface for new endothelium growth, i.e., will act as an in situ scaffolding through which endothelial cells may migrate. It will be understood by a person skilled in the art that any material with biocompatibility will be acceptable.
  • vascular patches In the case of vascular patches, one side of the patch engages the blood while the other side engages other surrounding tissues to promote transgraft growth of the endothelial cells. In the case of intracardiac patches, blood engages both sides of the patch.
  • Preferred biomaterials are those that provide sufficient rigidity in vivo.
  • a vascular patch biomaterial will be of sufficient rigidity to allow the patch to retain its form and pore-structure in the course of its intended use. The choice of patch material will differ according to the particular circumstances and site where the vascular patch is implanted.
  • Vascular patch is made of synthetic biomaterial, such materials include, but are not limited to, tetrafluoroethylene polymers, aromatic/aliphatic polyester resins, polyurethanes, and silicone rubbers, however, any type of biocompatible microporous mesh may be used.
  • the said biomaterials can be combined with each other or other substances such as polyglycolic acid.
  • Preferred are expanded polytetrafluoroethylene and Dacron. Dacron is usually woven, braided or knitted, and with or without velour, and suitable yarns are between 10 and 400 deniers.
  • the nodal regions of ePTFE are composed of nonporous PTFE that serves to provide tear resistance (e.g. for sutures and resistance to aneurismal dilatation).
  • the intemodal regions are composed of fibres of PTFE which serve to connect the nodes, with the spaces between the fibres providing the porosity referred to herein.
  • the nodal size can be expressed as the percentage of the tissue-contacting surface that is composed of nodal PTFE.
  • the distance between nodes can be expressed as the average fibril length.
  • the porosity is commonly expressed as the intemodal distance (i.e. the average distance from the middle of one node to the middle of adjacent node).
  • Preferred ePTFE materials have nodes of sufficient size and frequency to provide adequate strength (e.g., with respect to aneurismal dilatation) and intemodal regions of sufficient frequency and fibre length to provide adequate porosity (to allow for capillary endothelialisation).
  • Biomaterials are preferably porous to allow the attachment and migration of cells, which may be followed by the formation and growth of capillaries into the luminal surface.
  • Suitable pores can exist in the form of small channels or passages, which start at an external surface and extend through the biomaterial. In such cases, the cross sectional dimensions of the pores are larger than the diameter of a capillary 5 microns and are typically less than 1 mm.
  • Upper pore size value is not critical as long as the biomaterial retains sufficient rigidity.
  • pore size greater than about 1mm can be quantified in microscope.
  • proteins for example, 5,037,377, 4,319,363
  • non-heparinised whole blood and platelet rich plasma glow-discharge modifications of surfaces
  • adding pluronic gel, fibrin glue, adhesion molecules, covalent bonding influencing surface charges with for example carbon (5,827,327, 4,164,045), treating with a surfactant or cleaning agent, without excluding any other method.
  • the implant can be constructed as a hybrid of different intemodal distances in inner and outer surface, such as outer 60 microns and inner 20 microns in intemodal distance (HYBRID PTFE). Even more layers with different intemodal distances may be used. They all are intended to fall in the scope of present invention when not inhibiting endothelialisation.
  • Potential biodegradable materials may be used in connection with the compositions, devices and methods of this invention, for example homopolymers e.g.
  • poly-paradioxanone, polylysine or polyglycolic acid and copolymers e.g., polylactic acid and polyglycolic acids or other bio materials, such as matrices of purified proteins and semi-purified extra cellular matrix compositions may be used either alone or in combination with other materials as cardiovascular patch material, as long as they provide the required rigidity.
  • Naturally occuring autogenic, allogenic and xenogenic material such as an umbilical vein, saphenous vein, native bovine artery, pericardium or intestinal submucosal tissue may also be used as cardiovascular patch material. Examples of clinically used vascular patches are disclosed in 5,037,377, 5,456,711, 5,104,400, 4,164,045.
  • Appropriate vascular patches will both deliver the gene composition and also provide a surface for new endothelium growth, i.e., will act as an in situ scaffolding on which and through which endothelial cells may migrate.
  • nucleic acids are attached to the side engaging the tissues surrounding the vessel.
  • Appropriate intracardiac patches will both deliver the gene composition to the surrounding tissues and provide a surface for new endothelium growth, i.e., will act as an in situ scaffolding on which and through which endothelial cells may migrate.
  • nucleic acids are attached to both intracardiac patch surfaces.
  • nucleic acids may be attached to one of the intracardiac patch surfaces. It will be understood by a person skilled in the art that any material with biocompatibility, rigidity and porosity to allow endothelialisation will be acceptable.
  • Stent herein means a medical implant in the form of a hollow cylinder, which will provide support for the body lumen when it is implanted in contact with a site in the wall of a lumen to be treated.
  • They can be of several different designs such as tubular, conical or bifurcated.
  • the configuration can be such as a coiled spring, braided filament, perforated tube, slit tube, and zigzag, or any other variant.
  • it is adapted for use in blood vessels in a way that the stent has an outer, lumen-contacting surface, and an inner, blood-contacting surface.
  • stents of the art are formed of individual member(s), such as wire, plastic, metal strips, or mesh, which are bent, woven, interlaced or otherwise fabricated into a generally cylindrical configuration.
  • the stent can also have underlying polymeric or metallic structural elements, onto which elements; a film is applied (5,951.586).
  • Stents have been classified into either self- expanding or pressure expandable.
  • the terms expand, expanding, and expandable are used herein to refer to diametrically adjustable intraluminal stents.
  • the self expanding stents When the self expanding stents are positioned at the treatment site with a delivery catheter, they are supposed to radially expand to a larger diameter after being released from a constraining force, which force restricts them to a smaller diameter and conform a surface contact with a blood vessel wall or other tissue without exertion of outwardly directed radial force upon stent.
  • Stents of this type include stents of braided or formed wire.
  • the pressure-expandable stents are fabricated of malleable or plastically deformable material, typically formed of metal wire or metal strips. The collapsed stent is taken to the treatment site with a delivery catheter, and is then radially expanded with a balloon or other stent-expansion apparatus to its intended operative diameter.
  • Thread elements or strands formed of metal are generally favoured, for applications requiring flexibility and effective resistance to radial compression after implantation.
  • the favourable combination of strength and flexibility is largely due to the properties of the strands after they have been age hardened, or otherwise thermally treated in the case of polymeric strands.
  • the braiding angle of the helical strands and the axial spacing between adjacent strands also contributes to strength and flexibility.
  • Stent wires may be of metal, inorganic fibres or organic polymers. They should be elastic, strong, biocompatible, and fatigue and corrosion resistant.
  • core wires made of metals such as stainless steel or gold or other relatively pliable non-toxic metals and alloys that do not degrade during the time of implantation or are not subject to severe degradation (corrosion) under the influence of an electric current, are usually chosen.
  • metals include, but are not limited to, platinum, platinum-iridium alloys, copper alloys, with tin or titanium, nickel-chrome-cobalt alloys, cobalt based alloys, molybdenum alloys, nickel-titanium alloys.
  • the strands need not be of metal and may for example be of a polymeric material such as PET, polypropylene, PEEK, HDPE, polysulfone, acetyl, PTFE, FEP, and polyurethane without excluding any other substance (other variants: polytetrafluoroethylene, fluorinated ethylene propylene, polytetrafluoroethylene-perfluoroalkyl vinyl ether copolymer, polyvinyl chloride, polypropylene, polyethylene terephthalate, broad fluoride and other biocompatible plastics).
  • a biodegradable or bioabsorbable material such as homopolymers e.g.
  • poly-paradioxanone, polylysine or polyglycolic acid and copolymers may be used either alone or in combination with other materials as the stent material.
  • Such monofilament strands range from 0,002 to 0,015 inches in diameter but of course the diameter could vary depending on the lumen size and the degree of support needed.
  • To stents may also antithrombotic, anti-platelet, vasodilators, antiproliferative, antimigratory, antifibrotic, anti-inflammatory agents and more specifically, heparin, hirudin, hirulog, etritinate, freskolin and the like, be attached. Examples of clinically used stents are disclosed in 4,733,665, 4,800,882, 4,886,062 incorporated here by reference.
  • Stent grafts also called covered stents, for transluminal implantations include a resilient tubular interbraided latticework of metal or polymeric monofilaments, a tubular interbraided sleeve formed of a plurality of interwoven textile strands, and an attachment component that fixes the latticework and the sleeve together, in a selected axial alignment with one another, engaged with one another and with a selected one of the latticework and the sleeve surrounding the other, whereby the latticework structurally supports the sleeve.
  • the latticework and the sleeve behave according to substantially the same relationship governing the amount of radial reduction that accompanies a given axial elongation.
  • the sleeve may be exterior or interior to the latticework, or the latticework may be integrated in the sleeve, and it can be continuous or discontinuous.
  • Several prosthesis constructions have been suggested for composite braided structures that combine different types of strands, e.g. multifilament yarns, monofilaments, fusible, materials and collagens. Examples are found in WO91/10766. Textile strands are preferably multifilament yarns, even though they can be monofilaments.
  • the textile strands are much finer than the structural strands, ranging from about 10 denier to 400 denier.
  • Individual filaments of the multifilament yarns can range from about 0.25 to about 10 denier.
  • Multifilament yarns can be composed of various materials, such as PET, polypropylene, polyethylene, polyurethane, HDPE, silicone, PTFE, polyolefins and ePTFE.
  • Porous expanded PTFE film has a microstructure of nodes interconnected by fibrils and may be made as taught by for example U.S. Pat. Nos. 3,953,566, 4,187,390 and 4,482,516.
  • Suitable pores can exist in the form of small channels or passages starting at an external surface and extending through the biomaterial. In such cases the cross-sectional dimensions of the pores are larger than the diameter of a capillary 5 microns, and are typically less than 1 mm.
  • Upper pore size value is not critical so long as the biomaterial retains sufficient rigidity, however it is unlikely that useful devices would have pore size greater than about 1mm. Such pore dimensions can be quantified in microscope.
  • stent graft materials and surfaces can be made such as precoating with proteins, non-heparinised whole blood and platelet rich plasma, glow-discharge modifications of surfaces, adding pluronic gel, fibronectin, fibrin glue, adhesion molecules, covalent bonding, influencing surface charges with for example carbon (5,827,327, 4,164,045), treating with a surfactant or cleaning agent, mechanically changing the characteristics, such as adding grooves and changing the end angles without excluding any other method.
  • the implant can be constructed as a hybrid of different intemodal distances in inner and outer surface such as outer 60 microns and inner 20 microns in intemodal distance (HYBRID PTFE).
  • the fibrils can be uni-axially oriented, that is oriented in primarily one direction, or multiaxially oriented, that is, oriented in more than one direction.
  • expanded is used herein to refer to porous expanded PTFE. It will be understood by a person skilled in the art, that any material with biocompatibility and porosity to allow transgraft growth will be acceptable. Examples of clinically used stent grafts are disclosed in 5,957,974, 5,928,279, 5,925,075, 5,916,264.
  • stent grafts such as an umbilical vein, saphenous vein, or native bovine artery.
  • biodegradable vascular implants may be used as stent grafts in connection with the compositions, devices and methods of this invention, for example biodegradable and chemically defined polylactic acid, polyglycolic acid, matrices of purified proteins, semi-purified extra cellular matrix compositions.
  • vascular grafts and stent grafts will both deliver the gene composition and also provide a surface for new endothelium growth, i.e., will act as an in situ scaffolding through which endothelial cells may migrate.
  • the particular design of the implants that are implanted using the methods and compositions of the invention are not important, as long as they act as scaffolds through which endothelium can migrate, in the context of in vivo embodiments, and ultimately give rise to endothelialisation of the implant.
  • an expansion means is shaped as a helix 11, the diameter of which is reduced by stretching the helix and locking it prior to insertion, and unlocking the helix after insertion allowing the biocompatible cover to expand.
  • the locking of the expandable material prior to insertion is by using a locking thread 3 wound to and fro around the tubular conduit in conjunction and cooperation with a releasing, removable thread 4 arranged to be withdrawn from its locking position.
  • a locking thread 3 wound to and fro around the tubular conduit in conjunction and cooperation with a releasing, removable thread 4 arranged to be withdrawn from its locking position.
  • the locking thread is wound around the releasing thread to and fro.
  • the releasing thread 4 is drawn along the tubular conduit, and then the locking thread 3 is drawn to and fro said releasing thread 4, as shown in detail in FIG. 5.
  • the locking thread 3 may be removed from the site, i.e., from the site where the conduit 1 is inserted or may be made of any biocompatible resorbable material known in the art of suturing, such as a polylactic material.
  • An insertion device 6 may be used for stabilizing and holding the conduit 1 during insertion into two vessel parts V, as shown in FIG. 6.
  • the insertion device simultaneously is a counterpart for the withdrawal of the releasing thread 4.
  • the insertion device comprises guiding part 7 forming an enclosing grip of the conduit 1, and a handle 8 comprising a pair of eyes 9 to be used by the surgeon's fingers or the endoscope robotic arms for guiding the conduit 1 and acting as a counterpart when removing the thread 4.
  • the eyes 9 of the handle 8 are also connected to the guiding enclosing part 7 and is arranged to release said enclosing grip of the conduit.
  • any invasive method can be used to enter the site of preparing a shunt or other type of by-pass that is needed.
  • general surgery can be used as well as endoscopy where an endoscope is introduced through a blood vessel or the similar and is guided to the site.
  • the vessel to be provided with the anastomotic device is then closed up-stream the damaged site, a surgical incision is made to cut away any damaged tissue of the vessel, and the anastomotic device of the invention is brought into one end of the vessel and is then inserted into the other end of the vessel to be repaired.
  • the releasing thread is then removed from the anastomotic device by drawing it away.
  • the anastomotic device of the invention can also be used for by-pass surgery where one end of the anastomotic device is introduced into a vessel down-stream or upstream an occlusion, OS, and the vessel circumventing the occlusion is added to the other end of the device. See FIG. 7.
  • the vessel, CV circumventing the occlusion is seen up the left, whereby the releasing thread 4 has been removed from this part and the conduit has been allowed to expand, and whereby to the right the non-expanded part of the conduit 1 has just been entered into the vessel, V.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Surgical Instruments (AREA)

Abstract

L'invention concerne un dispositif d'anastomose qui comprend un connecteur de greffe tubulaire contenant un tube extensible, ce tube étant doté d'un dispositif de fermeture qui l'obture lorsqu'il n'est pas étiré, ainsi qu'un élément de libération conçu pour libérer le dispositif de fermeture après insertion dans un vaisseau, un conduit, une lumière, etc.
PCT/SE2003/000980 2002-06-11 2003-06-11 Dispositif d'anastomose, methode d'ouverture et anastomose chirurgicale par voie endoscopique Ceased WO2003103513A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003239015A AU2003239015A1 (en) 2002-06-11 2003-06-11 Anastomotic device and method for open and endoscopic surgical anatomosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201797-8 2002-06-11
SE0201797A SE0201797D0 (sv) 2002-06-11 2002-06-11 Anatstomotic device and method for open and endoscopic sugical anastomosis

Publications (1)

Publication Number Publication Date
WO2003103513A1 true WO2003103513A1 (fr) 2003-12-18

Family

ID=20288165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2003/000980 Ceased WO2003103513A1 (fr) 2002-06-11 2003-06-11 Dispositif d'anastomose, methode d'ouverture et anastomose chirurgicale par voie endoscopique

Country Status (3)

Country Link
AU (1) AU2003239015A1 (fr)
SE (1) SE0201797D0 (fr)
WO (1) WO2003103513A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1973497A4 (fr) * 2006-01-20 2011-03-02 Gore Enterprise Holdings Inc Dispositif de réparation rapide de conduits corporels
WO2012034108A1 (fr) * 2010-09-10 2012-03-15 Gore Enterprise Holdings, Inc. Dispositifs anastomotiques et procédures
CN102946825A (zh) * 2009-12-30 2013-02-27 恩朵罗杰克斯股份有限公司 用于移植系统的填充结构及其使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021402A1 (fr) * 1995-12-14 1997-06-19 Prograft Medical, Inc. Appareil et procede de deploiement de stent a greffer
US6264689B1 (en) * 1998-03-31 2001-07-24 Scimed Life Systems, Incorporated Low profile medical stent
US6280465B1 (en) * 1999-12-30 2001-08-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for delivering a self-expanding stent on a guide wire
US6371979B1 (en) * 1993-01-27 2002-04-16 Intratherapeutics, Inc. Stent delivery system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6371979B1 (en) * 1993-01-27 2002-04-16 Intratherapeutics, Inc. Stent delivery system
WO1997021402A1 (fr) * 1995-12-14 1997-06-19 Prograft Medical, Inc. Appareil et procede de deploiement de stent a greffer
US6264689B1 (en) * 1998-03-31 2001-07-24 Scimed Life Systems, Incorporated Low profile medical stent
US6280465B1 (en) * 1999-12-30 2001-08-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for delivering a self-expanding stent on a guide wire

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1973497A4 (fr) * 2006-01-20 2011-03-02 Gore Enterprise Holdings Inc Dispositif de réparation rapide de conduits corporels
US10357352B2 (en) 2006-01-20 2019-07-23 W. L. Gore & Associates, Inc. Device for rapid repair of body conduits
US9375215B2 (en) 2006-01-20 2016-06-28 W. L. Gore & Associates, Inc. Device for rapid repair of body conduits
US9381018B2 (en) 2006-01-20 2016-07-05 W. L. Gore & Associates, Inc. Device for rapid repair of body conduits
US11638638B2 (en) 2009-12-30 2023-05-02 Endologix Llc Filling structure for a graft system and methods of use
CN102946825A (zh) * 2009-12-30 2013-02-27 恩朵罗杰克斯股份有限公司 用于移植系统的填充结构及其使用方法
US9463269B2 (en) 2010-09-10 2016-10-11 W. L. Gore & Associates, Inc. Anastomotic devices and methods
US10245371B2 (en) 2010-09-10 2019-04-02 W. L. Gore & Associates, Inc. Anastomotic device and methods
CN103200975A (zh) * 2010-09-10 2013-07-10 W.L.戈尔及同仁股份有限公司 吻合装置和方法
EP4059536A1 (fr) * 2010-09-10 2022-09-21 W.L. Gore & Associates, Inc. Dispositifs anastomotiques
WO2012034108A1 (fr) * 2010-09-10 2012-03-15 Gore Enterprise Holdings, Inc. Dispositifs anastomotiques et procédures
US11833288B2 (en) 2010-09-10 2023-12-05 W. L. Gore & Associates, Inc. Anastomotic devices and methods
US12364798B2 (en) 2010-09-10 2025-07-22 W. L. Gore & Associates, Inc. Anastomotic devices and methods

Also Published As

Publication number Publication date
SE0201797D0 (sv) 2002-06-11
AU2003239015A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
US11395750B2 (en) Stent grafts and methods of use for treating aneurysms
US6406488B1 (en) Healing transmyocardial implant
JP4291955B2 (ja) ステント・グラフト・膜体及びその製造方法
JP3892907B2 (ja) 膨張可能で分岐した支持内腔移植片
US5197976A (en) Manually separable multi-lumen vascular graft
EP1759723B1 (fr) Chemise intraluminale
US5192311A (en) Medical implant and method of making
US20080200975A1 (en) Vascular Prosthesis with Anastomotic Member
US20020161383A1 (en) Devices and methods for interconnecting vessels
US20030139797A1 (en) Covered segmented stent
JP2002501777A (ja) 管腔内グラフト、管腔内ステント、または管腔内導管
AU2022228095B2 (en) Deployment constraining sheath that enables staged deployment by device section
JP2003514578A (ja) スパイダシルクによって被覆されたステント
CA2525577A1 (fr) Fixation etanche perfectionnee d'un stent endovasculaire a un greffon
KR20030017508A (ko) 맥관내 스텐트 이식편
WO2008038424A1 (fr) Vaisseau sanguin artificiel pour petite artère utilisant des fils de fibroïne
KR102394785B1 (ko) 대동맥 치료 장치
JPH0833719A (ja) 管腔臓器治療具
WO2003103513A1 (fr) Dispositif d'anastomose, methode d'ouverture et anastomose chirurgicale par voie endoscopique
RU187447U1 (ru) Биологический протез артерий с наружным сетчатым трубчатым покрытием внешней стенки

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP